Media April 15, 2025: Le Journal des biotechs : Hervé Affagard (Maat Pharma), Frédéric Gomez (Pharmium Securities) – Boursorama (French Only) MaaT PharmaApril 15, 2025
Media April 9, 2025: MaaT Pharma reports safety interim analysis from trial of microbiome therapy – Clinical Trials Arena MaaT PharmaApril 9, 2025
Media April 9, 2025: Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients – OncLive MaaT PharmaApril 9, 2025
Media April 1, 2025: MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies – BioTuesdays MaaT PharmaApril 1, 2025
Media March 20, 2025: DSMB Confirms MaaT013 Efficacy/Benefit in GI-aGvHD – Cancer Network MaaT PharmaMarch 20, 2025
Media February 20, 2025: Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations – Microbiome Times MaaT PharmaFebruary 24, 2025
Media February 10, 2025: MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology – Fierce Pharma MaaT PharmaFebruary 18, 2025
Media January 13, 2025: Microbiote : résultats positifs d’une étude clinique – Ouest France (French Only) MaaT PharmaJanuary 27, 2025
Media January 13, 2025: ARES Trial of MaaT013 in Acute GVHD Meets Primary End Point – Targeted Oncology MaaT PharmaJanuary 27, 2025
Media January 10, 2025: MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease – Cancer Network MaaT PharmaJanuary 27, 2025
